The potential of light therapy in Parkinson's disease

References

• Bergman H, Deuschl G. Pathophysiology of Parkinson’s disease: from clinical neurology to basic neuroscience and back. Mov Disord. 2002;17(Suppl 3):S28–S40.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376.
   PubMed Web of Science ®Google Scholar
• Rinne JO. Nigral degeneration in Parkinson’s disease. Mov Disord. 1993;(8 Suppl 1):S31–S35.
   Google Scholar
• Parent A. Carpenter’s Human Neuroanatomy. 9th ed. Baltimore, MD: Williams and Wilkins; 1996.
   Google Scholar
• Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson’s disease. Prog Neurobiol. 2000;62(1):63–88.
   PubMed Web of Science ®Google Scholar
• Schober A. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res. 2004;318(1):215–224.
   PubMed Web of Science ®Google Scholar
• Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol. 2012;2012:845618.
   PubMedGoogle Scholar
• Bové J, Perier C. Neurotoxin-based models of Parkinson’s disease. Neuroscience. 2012;211:51–76.
   PubMed Web of Science ®Google Scholar
• Bezard E, Dovero S, Imbert C, Boraud T, Gross CE. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse. 2000;38(3):363–368.
   Web of Science ®Google Scholar
• Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet. 2006;7(4):306–318.
   PubMed Web of Science ®Google Scholar
• Corti O, Brice A. Mitochondrial quality control turns out to be the principal suspect in parkin and PINK1-related autosomal recessive Parkinson’s disease. Curr Opin Neurobiol. 2013;23(1):100–108.
   Web of Science ®Google Scholar
• Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34(4):521–533.
   PubMed Web of Science ®Google Scholar
• Ittner LM, Fath T, Ke YD, et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A. 2008;105(41):15997–16002.
   PubMed Web of Science ®Google Scholar
• Muqit MM, Abou-Sleiman PM, Saurin AT, et al. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem. 2006;98(1):156–169.
   Web of Science ®Google Scholar
• Exner N, Lutz AK, Haass C, Winklhofer KF. Mitochondrial dysfunction in Parkinson’s disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012;31(14):3038–3062.
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9(1):13–24.
   PubMed Web of Science ®Google Scholar
• Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology. 1992;42(4):733–738.
   Web of Science ®Google Scholar
• Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci. 1993;13(10):4181–4192.
   PubMed Web of Science ®Google Scholar
• Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci. 1996;8(7):1408–1414.
   Web of Science ®Google Scholar
• Wallace BA, Ashkan K, Heise CE, et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain. 2007;130(Pt 8):2129–2145.
   PubMedGoogle Scholar
• Whitton PS. Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson’s disease. Curr Opin Investig Drugs. 2010;11(7):788–794.
   Google Scholar
• McGeer PL, McGeer EG. Glial reactions in Parkinson’s disease. Mov Disord. 2008;23(4):474–483.
   PubMed Web of Science ®Google Scholar
• Jankovic P, Poewe W. Therapies in Parkinson’s disease. Curr Opin Neurol. 2012;25(4):433–447.
   PubMed Web of Science ®Google Scholar
• Schapira AH. Present and future drug treatment for Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2005;76(11):1472–1478.
   PubMed Web of Science ®Google Scholar
• Worth PF. How to treat Parkinson’s disease in 2013. Clin Med. 2013 13(1):93–96.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson’s disease: systematic review. Mov Disord. 2009; 24(5):647–654.
   Web of Science ®Google Scholar
• Ashkan K, Wallace B, Bell BA, Benabid AL. Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease 1993–2003: where are we 10 years on? Br J Neurosurg. 2004;18(1):19–34.
   Google Scholar
• Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol. 2009;8(1):67–81.
   PubMed Web of Science ®Google Scholar
• Charles PD, Gill CE, Davis TL, Konrad PE, Benabid AL. Is deep brain stimulation neuroprotective if applied early in the course of PD? Nat Clin Pract Neurol. 2008;4(8):424–426.
   PubMedGoogle Scholar
• Stocchi F, Olanow CW. Obstacles to the development of a neuroprotective therapy for Parkinson’s disease. Mov Disord. 2013;28(1):3–7.
   Web of Science ®Google Scholar
• Kordower JH, Bjorklund A. Trophic factor gene therapy for Parkinson’s disease. Mov Disord. 2013;28(1):96–109.
   PubMed Web of Science ®Google Scholar
• Maruyama W, Naoi M. “70th Birthday Professor Riederer” induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy? J Neural Transm. 2013;120(1):83–89.
   Google Scholar
• Arias-Carrión O, Yamada E, Freundlieb N, et al. Neurogenesis in substantia nigra of parkinsonian brains? J Neural Transm Suppl. 2009;(73):279–285.
   Google Scholar
• Grazina R, Massano J. Physical exercise and Parkinson’s disease: influence on symptoms, disease course and prevention. Rev Neurosci. 2013;24(2):139–152.
   Web of Science ®Google Scholar
• Kones R. Parkinson’s disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition. Nutr Clin Pract. 2010;25(4):371–389.
   Web of Science ®Google Scholar
• Romeo S, Viaggi C, Di Camillo D, et al. Bright light exposure reduces TH-positive dopamine neurons: implications of light pollution in Parkinson’s disease epidemiology. Sci Rep. 2013;3:1395.
   Web of Science ®Google Scholar
• Eells JT, Henry MM, Summerfelt P, et al. Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc Natl Acad Sci U S A. 2003;100(6):3439–3444.
   PubMed Web of Science ®Google Scholar
• Natoli R, Zhu Y, Valter K, Bisti S, Eells J, Stone J. Gene and noncoding RNA regulation underlying photoreceptor protection: microarray study of dietary antioxidant saffron and photobiomodulation in rat retina. Mol Vis. 2010;16:1801–1822.
   PubMed Web of Science ®Google Scholar
• Natoli R, Valter K, Barbosa M, et al. 670 nm photobiomodulation as a novel protection against retinopathy of prematurity: evidence from oxygen induced retinopathy models. PLoS One. 2013;8(8):e72135.
   Web of Science ®Google Scholar
• Albarracin R, Valter K. 670 nm red light preconditioning supports Müller cell function: evidence from the white light-induced damage model in the rat retina. Photochem Photobiol. 2012;88(6):1418–1427.
   PubMed Web of Science ®Google Scholar
• Begum R, Powner MB, Hudson N, Hogg C, Jeffery G. Treatment with 670 nm light up regulates cytochrome C oxidase expression and reduces inflammation in an age-related macular degeneration model. PloS One. 2013;8(2):e57828.
   Web of Science ®Google Scholar
• Ando T, Xuan W, Xu T, et al. Comparison of therapeutic effects between pulsed and continuous wave 810-nm wavelength laser irradiation for traumatic brain injury in mice. PLoS One. 2011;6(10):e26212.
   PubMed Web of Science ®Google Scholar
• Oron A, Oron U, Streeter J, et al. Near infrared transcranial laser therapy applied at various modes to mice following traumatic brain injury significantly reduces long-term neurological deficits. J Neurotrauma. 2012;29(2):401–407.
   Web of Science ®Google Scholar
• Quirk BJ, Torbey M, Buchmann E, Verma S, Whelan HT. Near-infrared photobiomodulation in an animal model of traumatic brain injury: improvements at the behavioral and biochemical levels. Photomed Laser Surg. 2012;30(9):523–529.
   Web of Science ®Google Scholar
• Lapchak PA, Wei J, Zivin JA. Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke. 2004;35(8):1985–1988.
   Web of Science ®Google Scholar
• De Taboada L, Ilic S, Leichliter-Martha S, Oron U, Oron A, Streeter J. Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke. Lasers Surg Med. 2006;38(1):70–73.
   Web of Science ®Google Scholar
• Oron A, Oron U, Chen J, et al. Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. Stroke. 2006;37(10):2620–2624.
   Web of Science ®Google Scholar
• Moges H, Vasconcelos OM, Campbell WW, et al. Light therapy and supplementary Riboflavin in the SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis (FALS). Lasers Surg Med. 2009; 41(1):52–59.
   Web of Science ®Google Scholar
• Muili KA, Gopalakrishnan S, Meyer SL, Eells JT, Lyons JA. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by photobiomodulation induced by 670 nm light. PLoS One. 2012;7(1):e30655.
   PubMed Web of Science ®Google Scholar
• Liang HL, Whelan HT, Eells JT, Wong-Riley MT. Near-infrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ion-induced neurotoxicity. Neuroscience. 2008;153(4):963–974.
   Web of Science ®Google Scholar
• Ying R, Liang HL, Whelan HT, Eells JT, Wong-Riley MT. Pretreatment with near-infrared light via light-emitting diode provides added benefit against rotenone- and MPP+-induced neurotoxicity. Brain Res. 2008;1243:167–173.
   PubMed Web of Science ®Google Scholar
• Whelan H, Desmet K, Buchmann E, et al. Harnessing the cell’s own ability to repair and prevent neurodegenerative disease. SPIE Newsroom. 2008;2008:1–3.
   Google Scholar
• Shaw VE, Spana S, Ashkan K, et al. Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment. J Comp Neurol. 2010;518(1):25–40.
   Web of Science ®Google Scholar
• Peoples CL, Spana S, Ashkan K, et al. Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(5):469–476.
   Web of Science ®Google Scholar
• Michalikova S, Ennaceur A, van Rensburg R, Chazot PL. Emotional responses and memory performance of middle-aged CD1 mice in a 3D maze: effects of low infrared light. Neurobiol Learn Mem. 2008;89(4):480–488.
   Web of Science ®Google Scholar
• De Taboada L, Yu J, El-Amouri S, et al. Transcranial laser therapy attenuates amyloid-β peptide neuropathology in amyloid-β protein precursor transgenic mice. J Alzheimers Dis. 2011;23(3):521–535.
   Web of Science ®Google Scholar
• Grillo SL, Duggett NA, Ennaceur A, Chazot PL. Non-invasive infra-red therapy (1072 nm) reduces β-amyloid protein levels in the brain of an Alzheimer’s disease mouse model, TASTPM. J Photochem Photobiol B. 2013;123:13–22.
   Web of Science ®Google Scholar
• Barrett DW, Gonzalez-Lima F. Transcranial infrared laser stimulation produces beneficial cognitive and emotional effects in humans. Neuroscience. 2013;230:13–23.
   PubMed Web of Science ®Google Scholar
• Lampl Y, Zivin JA, Fisher M, et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke. 2007;38(6):1843–1849.
   Web of Science ®Google Scholar
• Lapchak PA. Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. Ann Med. 2010;42(8):576–586.
   PubMed Web of Science ®Google Scholar
• Naeser MA, Saltmarche A, Krengel MH, Hamblin MR, Knight JA. Improved cognitive function after transcranial, light-emitting diode treatments in chronic, traumatic brain injury: two case reports. Photomed Laser Surg. 2011;29(5):351–358.
   PubMed Web of Science ®Google Scholar
• Schiffer F, Johnston AL, Ravichandran C, et al. Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. Behav Brain Funct. 2009;5:46.
   PubMed Web of Science ®Google Scholar
• Merry G, Devenyi R, Dotson R, Markowitz S, Reyes S. Treatment of dry age-related macular degeneration with photobiomodulation. Presented in: Proceedings of the 9th World Association of Laser Therapy Congress; September 28–30, 2012; Gold Coast (Australia). Paper P928C0072.
   Google Scholar
• Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. Circ Res. 2012;111(9):1198–1207.
   PubMed Web of Science ®Google Scholar
• Desmet KD, Paz DA, Corry JJ, et al. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg. 2006;24(2):121–128.
   PubMed Web of Science ®Google Scholar
• Hamblin MR, Demidova TN. Mechanisms of low level light therapy. Proc SPIE. 2006;6140:614001.
   Google Scholar
• Rojas JC, Gonzalez-Lima F. Low-level light therapy of the eye and brain. Eye and Brain. 2011;3:49–67.
   PubMedGoogle Scholar
• Chung H, Dai T, Sharma SK, Huang YY, Carroll JD, Hamblin MR. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2012;40(2):516–533.
   PubMed Web of Science ®Google Scholar
• Quirk BJ, Whelan HT. Near-infrared irradiation photobiomodulation: the need for basic science. Photomed Laser Surg. 2011;29(3):143–144.
   Web of Science ®Google Scholar
• Braverman B, McCarthy RJ, Ivankovich AD, Forde DE, Overfield M, Bapna MS. Effect of helium-neon and infrared laser irradiation on wound healing in rabbits. Lasers Surg Med. 1989;9(1):50–58.
   Web of Science ®Google Scholar
• Stone J, Johnstone DM, Mitrofanis J. The helmet experiment in Parkinson’s disease: an observation of the mechanism of neuroprotection by near infra-red light. Presented in: Proceedings of the 9th World Association of Laser Therapy Congress; September 28–30, 2012; Gold Coast (Australia). Paper P928C0072.
   Google Scholar
• Johnstone DM, Moro C, el Massri N, Torres N, Jaeger XD, Reinhart F, Purushothuman S, Benabid AL, Stone J, Mitrofanis J. Indirect application of near infrared light induces neuroprotection in a mouse model of Parkinson’s disease – an abscopal neuroprotective effect. In preparation. 2014. In press.
   Google Scholar
• Byrnes KR, Waynant RW, Ilev IK, et al. Light promotes regeneration and functional recovery and alters the immune response after spinal cord injury. Lasers Surg Med. 2005;36(3):171–185.
   PubMed Web of Science ®Google Scholar
• Tuby H, Maltz L, Oron U. Modulations of VEGF and iNOS in the rat heart by low level laser therapy are associated with cardioprotection and enhanced angiogenesis. Lasers Surg Med. 2006;38(7):682–688.
   Web of Science ®Google Scholar
• Tuby H, Maltz L, Oron U. Induction of autologous mesenchymal stem cells in the bone marrow by low-level laser therapy has profound beneficial effects on the infarcted rat heart. Lasers Surg Med. 2011;43(5):401–409.
   Web of Science ®Google Scholar
• Hou ST, Jiang SX, Smith RA. Permissive and repulsive cues and signalling pathways of axonal outgrowth and regeneration. Int Rev Cell Mol Biol. 2008;267:125–181.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–931.
   PubMed Web of Science ®Google Scholar
• Moro C, el Massri N, Torres N, et al. Photobiomodulation inside the brain: a novel method of applying near-infrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice. J Neurosurgery. Epub October 25, 2014.
   Google Scholar
• Moro C, Torres N, el Massri N, et al. Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains. BMC Neurosci. 2013;14:40.
   PubMed Web of Science ®Google Scholar
• Purushothuman S, Nandasena C, Johnstone DM, Stone J, Mitrofanis J. The impact of near-infrared light on dopaminergic cell survival in a transgenic mouse model of parkinsonism. Brain Res. 2013;1535:61–70.
   PubMed Web of Science ®Google Scholar
• Trimmer PA, Schwartz KM, Borland MK, De Taboada L, Streeter J, Oron U. Reduced axonal transport in Parkinson’s disease cybrid neurites is restored by light therapy. Mol Neurodegener. 2009;4:26.
   Web of Science ®Google Scholar
• Ashkan K, Wallace BA, Mitrofanis J, et al. SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(5):266–275.
   Web of Science ®Google Scholar
• Peoples C, Shaw VE, Stone J, Jeffery G, Baker GE, Mitrofanis J. Survival of dopaminergic amacrine cells after near-infrared light treatment in MPTP-treated mice. ISRN Neurol. 2012;2012:850150.
   Google Scholar
• Lu J, Jhou TC, Saper CB. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci. 2006;26(1):193–202.
   PubMed Web of Science ®Google Scholar
• Shaw VE, Peoples C, Spana S, et al. Patterns of cell activity in the subthalamic region associated with the neuroprotective action of near-infrared light treatment in MPTP-treated mice. Parkinson’s Dis. 2012;2012:296875.
   Web of Science ®Google Scholar
• DeSmet K, Buchmann E, Henry M, et al. Near-infrared light as a possible treatment option for Parkinson’s disease and laser eye injury. Proc SPIE. 2009;7165:7 16503.
   Google Scholar
• Quirk BJ, Desmet KD, Henry M, et al. Therapeutic effect of near infrared (NIR) light on Parkinson’s disease models. Front Biosci (Elite Ed). 2012;4:818–823.
   PubMedGoogle Scholar
• Lanzafame RJ, Stadler I, Kurtz AF, et al. Reciprocity of exposure time and irradiance on energy density during photoradiation on wound healing in a murine pressure ulcer model. Lasers Surg Med. 2007;39(6):534–542.
   Web of Science ®Google Scholar
• Quietmind Foundation. Quietmind Foundation clinical Trial. Available from: http://www.quietmindfdn.org/. Marvin Berman. 2013. http://www.youtube.com/watch?v=9X-hjgay7pg. Accessed January16, 2012.
   Google Scholar
• Maloney R, Shanks S, Maloney J. The application of low-level laser therapy for the symptomatic care of late stage Parkinson’s disease: a non-controlled, non-randomized study. April 14–15, 2010. Am Soc Laser Med Surg Abs. 2010;185.
   Google Scholar
• Li Q, Song L, Guo K, Yu Y, Ma S, Shen L. [The effect of endonasal low energy He-Ne laser treatment of Parkinson’s disease on CCK-8 content in blood]. Chin J Neurol. 1999;32:364. Chinese.
   Google Scholar
• Xu C, Lu C, Wang L, Li Q. [The effects of endonasal low energy He-Ne laser therapy on antioxydation of Parkinson’s disease]. Prac J Med Pharm. 2003;11:816–817. Chinese.
   Google Scholar
• Zhao G, Guo K, Dan J. [36 case analysis of Parkinson’s disease treated by endonasal low energy He-Ne laser]. Acta Academiae medicinae Qingdao Universitatis. 2003;39:398. Chinese.
   Google Scholar
• Burchman MA. Using Photobiomodulation on a severe Parkinson’s patient to enable extractions, root canal treatment and partial denture fabrication. J Laser Dent. 2011;19:297–300.
   Google Scholar
• Wong-Riley MT, Liang HL, Eells JT, et al. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J Biol Chem. 2005;280(6):4761–4771.
   Web of Science ®Google Scholar
• Eells JT, DeSmet K, Kirk DK, et al. Photobiomodulation for the treatment of retinal injury and retinal degenerative diseases. Proceed Light-Activated Tissue Regeneration Therapy Conference. 2008;12:39–51.
   Google Scholar
• Zivin JA, Albers GW, Bornstein N, et al; NeuroThera Effectiveness and Safety Trial-2 Investigators. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke. 2009;40(4):1359–1364.
   Google Scholar
• Jagdeo JR, Adams LE, Brody NI, Siegel DM. Transcranial red and near infrared light transmission in a cadaveric model. PLoS One. 2012;7(10):e47460.
   Web of Science ®Google Scholar
• Abdo A, Sahin M. . NIR Light Penetration Depth in the Rat Peripheral Nerve and Brain Cortex. In: Conference Proceedings of the IEEE. Eng Med Biol Soc. 2007:1723–1725. doi:10.1109/IEMBS.2007. 4352642.
   Google Scholar
• Torres N, Chabardes S, Piallat B, Devergnas A, Benabid AL. Body fat and body weight reduction following hypothalamic deep brain stimulation in monkeys: an intraventricular approach. Int J Obes (Lond). 2012;36(12):1537–1544.
   Web of Science ®Google Scholar
• Samuel M, Ceballos-Baumann AO, Blin J, et al. Evidence for lateral premotor and parietal overactivity in Parkinson’s disease during sequential and bimanual movements. A PET study. Brain. 1997; 120(Pt 6):963–976.
   Google Scholar
• Sabatini U, Boulanouar K, Fabre N, et al. Cortical motor reorganization in akinetic patients with Parkinson’s disease: a functional MRI study. Brain. 2000;123(Pt 2):394–403.
   PubMed Web of Science ®Google Scholar
• Haslinger B, Erhard P, Kämpfe N, et al. Event-related functional magnetic resonance imaging in Parkinson’s disease before and after levodopa. Brain. 2001;124(Pt 3):558–570.
   Google Scholar
• LeWitt PA. Neuroprotection for Parkinson’s disease. J Neural Transm Suppl. 2006;71:113–122.
   Google Scholar
• Ma J, Shaw VE, Mitrofanis J. Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkinsonism Relat Disord. 2009;15(4):307–314.
   Web of Science ®Google Scholar
• Ilic S, Leichliter S, Streeter J, Oron A, DeTaboada L, Oron U. Effects of power densities, continuous and pulse frequencies, and number of sessions of low-level laser therapy on intact rat brain. Photomed Laser Surg. 2006;24(4):458–466.
   Web of Science ®Google Scholar
• McCarthy TJ, De Taboada L, Hildebrandt PK, Ziemer EL, Richieri SP, Streeter J. Long-term safety of single and multiple infrared transcranial laser treatments in Sprague-Dawley rats. Photomed Laser Surg. 2010;28(5):663–667.
   Web of Science ®Google Scholar
• Tata DB, Waynant RW. Laser therapy: a review of its mechanism of action and potential medical applications. Laser Photonics Rev. 2011;5(1):1–12.
   Web of Science ®Google Scholar